Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (NYSE: MCK) is a diversified healthcare services and pharmaceutical distribution company that regularly issues news and updates relevant to investors, healthcare partners, and other stakeholders. The company describes itself as dedicated to advancing health outcomes for patients everywhere, partnering with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services that support access to quality care.
The McKesson news feed typically features announcements about quarterly and annual financial results, earnings release dates, and related investor webcasts. These updates often include information about fiscal guidance, long-term financial targets, and commentary on strategic priorities and business outlook shared during events such as Investor Day.
In addition to earnings and guidance, McKesson’s news includes Board actions such as dividend declarations, reflecting decisions on returning capital to shareholders. The company also issues releases on organizational and segment reporting changes, including the introduction of its North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions segments, along with portfolio developments like planned separations or divestitures.
McKesson may also appear in third-party announcements highlighting distribution agreements and collaborations that illustrate its role in pharmaceutical distribution and healthcare services. Such items can show how McKesson supports access to therapies through its distribution networks and healthcare supply chain capabilities.
For readers tracking MCK news, this page provides a centralized view of financial announcements, strategic updates, capital allocation decisions, and partnership-related developments. Regularly reviewing these items can help investors and observers understand how McKesson communicates its performance, segment evolution, and strategic focus within the healthcare and wholesale trade landscape.
McKesson Corporation (NYSE: MCK) will announce its first quarter fiscal 2023 financial results on August 3, 2022, after market close. The company will conduct a live webcast at 4:30 PM Eastern Time to discuss the results. Investors can access the webcast and related financial documentation on the company’s Investor Relations website. McKesson is committed to improving health outcomes and providing affordable healthcare solutions through partnerships with various stakeholders in the healthcare sector.
McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research arms, US Oncology Research and Sarah Cannon Research Institute, enhancing clinical trial access and drug development. This venture aims to expand oncology research, streamline trial matching for patients, and improve access, particularly for underserved communities. McKesson will hold 51% ownership, with the joint venture expected to close in 2022. Financial details remain undisclosed, and the agreement is subject to regulatory approvals.
McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research efforts, enhancing clinical trials and treatment options for cancer patients. The venture will merge McKesson’s US Oncology Research with HCA’s Sarah Cannon Research Institute, aiming to improve access and accelerate cancer drug development, especially in underserved communities. McKesson will hold a 51% stake and operating control. The deal is expected to close in 2022, pending regulatory approval and customary conditions.
McKesson Corporation (NYSE: MCK) announced its fiscal 2022 fourth-quarter financial results, which are accessible through its Investor Relations website. A live webcast of the earnings conference call is scheduled for May 5 at 4:30 PM ET, allowing investors to review the results in detail. McKesson aims to enhance healthcare accessibility and affordability through partnerships with various healthcare entities. More information is available on their official website.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Washington Attorney General, agreeing to pay up to $518 million. This payment resolves lawsuits filed by the state and its subdivisions, allowing for the dismissal of ongoing litigation. The settlement aligns with a previously announced agreement effective April 2, 2022, aimed at addressing a significant portion of opioid claims against the distributors. The companies dispute the allegations but see this as steps toward broader resolutions and relief for impacted communities.
The Board of Directors of McKesson Corporation (NYSE:MCK) has declared a regular dividend of 47 cents per share of common stock. This dividend will be payable on July 1, 2022, to stockholders of record on June 1, 2022. McKesson Corporation is a leader in healthcare services, focusing on enhancing health outcomes through partnerships with various stakeholders in the industry, including biopharma companies and care providers. For further information, visit McKesson.com.
McKesson Corporation (NYSE: MCK) has successfully closed the sale of its UK businesses to AURELIUS, enhancing its focus on streamlining operations and exiting the European market.
The company is set to report its fourth quarter fiscal 2022 financial results on May 5, 2022, with a live earnings conference call at 4:30 PM ET. Further comments on the sale will be provided during this call, with the earnings release and financial details accessible on McKesson's Investor Relations website.
McKesson Corporation (NYSE: MCK) announced the election of W. Roy Dunbar as a new director and member of the Audit and Governance Committees, effective April 1, 2022. This expands the board from 11 to 12 members, with 11 being independent. Dunbar brings extensive experience from roles at Network Solutions, Mastercard, and Eli Lilly, focusing on technology, operations, and sustainability. His addition is expected to enhance the board's oversight, particularly in oncology, biopharma, data governance, and cybersecurity.
Settlement Announcement: AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have reached an agreement to settle the majority of opioid lawsuits with participation from 46 of 49 eligible states and over 90% of litigating political subdivisions. The settlement totals approximately $19.5 billion to be distributed over 18 years, with individual contributions of $6.1 billion, $6.0 billion, and $7.4 billion from AmerisourceBergen, Cardinal Health, and McKesson, respectively. The agreement aims to provide relief to communities affected by the opioid crisis.
McKesson Corporation (NYSE: MCK) announced its fiscal 2022 third-quarter financial results. Investors can access detailed results through the company's Investor Relations website. A live webcast of the earnings conference call will be held on February 2 at 4:30 PM ET, where management will discuss financial performance. McKesson has been recognized as a leading healthcare supply chain management provider and is noted for its commitment to patient health through innovative healthcare solutions.